The Global Health Body Sounds Concern Over Critical Lack of Weight-Loss Medications

Less than 10% of patients that would benefit from weight-loss injections including Wegovy have access to them, warns the World Health Organization as it publishes its initial recommendations on the therapies.

With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for increased and just availability to GLP-1 medication.

Per forecasts, more than two billion are projected to be living with obesity by 2030 without intervention.

"The latest guidelines affirms that obesity is a long-term condition that can be addressed with comprehensive and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and supply-chain constraints are key obstacles to broad access to the treatments that can aid individuals in losing significant weight, notes the organization.

GLP-1 Therapy Shortage

Despite the current best projected outlook, the supply of these medications would only suffice for about 100 million people – under 10% of eligible patients, per the health organization.

The advice urges nations and manufacturers to widen access, through measures including patent sharing.

A patent on a key compound – the main ingredient of a leading brand – is due to expire in several countries in 2026.

The Way Weight-Loss Injections Function

GLP-1 drugs imitate a body's own hormone to reduce digestion speed, reduce hunger and boost satiety so people eat less.

People usually start to lose weight after several weeks of commencing the weekly injections.

Research suggests patients may see weight return a year later of discontinuing the medication, because their typical hunger return.

Being overweight or obese elevates your risk for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and some cancers.

Obesity concerns individuals in every country and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.